ProCE Banner Activity

LA CAB/RPV + LEN in People With HIV, Adherence Challenges, and INSTI/NNRTI Resistance Mutations

Conference Coverage
Slideset

In an analysis of 9 people with adherence challenges and INSTI/NNRTI resistance-associated mutations, virologic suppression was maintained through 24-36 weeks of follow-up with LA CAB/RPV + LEN for HIV treatment.

Released: October 24, 2024

Expiration: October 23, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc. and ViiV Healthcare.

Gilead Sciences, Inc.

ViiV Healthcare